Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study

Seok Jin Kim, Jun Sik Hong, Myung Hee Chang, Jeong A. Kim, Jae Yong Kwak, Jin Seok Kim, Dok Hyun Yoon, Won Sik Lee, Young Rok Do, Hye Jin Kang, Hyeon Seok Eom, Yong Park, Jong Ho Won, Yeung Chul Mun, Hyo Jung Kim, Jung Hye Kwon, Jee Hyun Kong, Sung Yong Oh, Sunah Lee, Sung Hwa BaeDeok Hwan Yang, Hyun Jung Jun, Yang Soo Kim, Hwan Jung Yun, Soon Il Lee, Min Kyoung Kim, Eun Kyung Park, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Central nervous system involvement remains a challenging issue in the treatment of patients with diffuse large B-cell lymphoma. We conducted a prospective cohort study with newly diagnosed diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone to identify incidence and risk factors for central nervous system involvement. Among 595 patients, 279 patients received pre-treatment central nervous system evaluation, and 14 patients had central nervous system involvement at diagnosis (2.3% out of entire patients and 5.0% out of the 279 patients). For those patients, median followup duration was 38.2 months and some of them achieved long-term survival. Out of 581 patients who did not have central nervous system involvement at diagnosis, 26 patients underwent secondary central nervous system relapse with a median follow-up of 35 months, and the median time to central nervous system involvement was 10.4 months (range: 3.4-29.2). Serum lactate dehydrogenase > ×3 upper limit of normal range, the Eastern Cooperative Oncology Group performance status ≥ 2, and involvement of sinonasal tract or testis, were independent risk factors for central nervous system relapse in multivariate analysis. Our study suggests that enhanced stratification of serum lactate dehydrogenase according to the National Comprehensive Cancer Network-International Prognostic Index may contribute to better prediction for central nervous system relapse in patients with diffuse large B-cell lymphoma.

Original languageEnglish
Pages (from-to)72033-72043
Number of pages11
JournalOncotarget
Volume7
Issue number44
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
L-Lactate Dehydrogenase
Cohort Studies
Central Nervous System
Prospective Studies
Recurrence
Serum
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Testis
Reference Values
Multivariate Analysis

Keywords

  • Central nervous system
  • Diffuse large B-cell lymphoma
  • Lactate dehydrogenase
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Cite this

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma : Results of a multicenter prospective cohort study. / Kim, Seok Jin; Hong, Jun Sik; Chang, Myung Hee; Kim, Jeong A.; Kwak, Jae Yong; Kim, Jin Seok; Yoon, Dok Hyun; Lee, Won Sik; Do, Young Rok; Kang, Hye Jin; Eom, Hyeon Seok; Park, Yong; Won, Jong Ho; Mun, Yeung Chul; Kim, Hyo Jung; Kwon, Jung Hye; Kong, Jee Hyun; Oh, Sung Yong; Lee, Sunah; Bae, Sung Hwa; Yang, Deok Hwan; Jun, Hyun Jung; Kim, Yang Soo; Yun, Hwan Jung; Lee, Soon Il; Kim, Min Kyoung; Park, Eun Kyung; Kim, Won Seog; Suh, Cheolwon.

In: Oncotarget, Vol. 7, No. 44, 01.01.2016, p. 72033-72043.

Research output: Contribution to journalArticle

Kim, SJ, Hong, JS, Chang, MH, Kim, JA, Kwak, JY, Kim, JS, Yoon, DH, Lee, WS, Do, YR, Kang, HJ, Eom, HS, Park, Y, Won, JH, Mun, YC, Kim, HJ, Kwon, JH, Kong, JH, Oh, SY, Lee, S, Bae, SH, Yang, DH, Jun, HJ, Kim, YS, Yun, HJ, Lee, SI, Kim, MK, Park, EK, Kim, WS & Suh, C 2016, 'Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study', Oncotarget, vol. 7, no. 44, pp. 72033-72043. https://doi.org/10.18632/oncotarget.12459
Kim, Seok Jin ; Hong, Jun Sik ; Chang, Myung Hee ; Kim, Jeong A. ; Kwak, Jae Yong ; Kim, Jin Seok ; Yoon, Dok Hyun ; Lee, Won Sik ; Do, Young Rok ; Kang, Hye Jin ; Eom, Hyeon Seok ; Park, Yong ; Won, Jong Ho ; Mun, Yeung Chul ; Kim, Hyo Jung ; Kwon, Jung Hye ; Kong, Jee Hyun ; Oh, Sung Yong ; Lee, Sunah ; Bae, Sung Hwa ; Yang, Deok Hwan ; Jun, Hyun Jung ; Kim, Yang Soo ; Yun, Hwan Jung ; Lee, Soon Il ; Kim, Min Kyoung ; Park, Eun Kyung ; Kim, Won Seog ; Suh, Cheolwon. / Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma : Results of a multicenter prospective cohort study. In: Oncotarget. 2016 ; Vol. 7, No. 44. pp. 72033-72043.
@article{6bc4a0a19ba642cda00592cf09956436,
title = "Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study",
abstract = "Central nervous system involvement remains a challenging issue in the treatment of patients with diffuse large B-cell lymphoma. We conducted a prospective cohort study with newly diagnosed diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone to identify incidence and risk factors for central nervous system involvement. Among 595 patients, 279 patients received pre-treatment central nervous system evaluation, and 14 patients had central nervous system involvement at diagnosis (2.3{\%} out of entire patients and 5.0{\%} out of the 279 patients). For those patients, median followup duration was 38.2 months and some of them achieved long-term survival. Out of 581 patients who did not have central nervous system involvement at diagnosis, 26 patients underwent secondary central nervous system relapse with a median follow-up of 35 months, and the median time to central nervous system involvement was 10.4 months (range: 3.4-29.2). Serum lactate dehydrogenase > ×3 upper limit of normal range, the Eastern Cooperative Oncology Group performance status ≥ 2, and involvement of sinonasal tract or testis, were independent risk factors for central nervous system relapse in multivariate analysis. Our study suggests that enhanced stratification of serum lactate dehydrogenase according to the National Comprehensive Cancer Network-International Prognostic Index may contribute to better prediction for central nervous system relapse in patients with diffuse large B-cell lymphoma.",
keywords = "Central nervous system, Diffuse large B-cell lymphoma, Lactate dehydrogenase, Prognosis",
author = "Kim, {Seok Jin} and Hong, {Jun Sik} and Chang, {Myung Hee} and Kim, {Jeong A.} and Kwak, {Jae Yong} and Kim, {Jin Seok} and Yoon, {Dok Hyun} and Lee, {Won Sik} and Do, {Young Rok} and Kang, {Hye Jin} and Eom, {Hyeon Seok} and Yong Park and Won, {Jong Ho} and Mun, {Yeung Chul} and Kim, {Hyo Jung} and Kwon, {Jung Hye} and Kong, {Jee Hyun} and Oh, {Sung Yong} and Sunah Lee and Bae, {Sung Hwa} and Yang, {Deok Hwan} and Jun, {Hyun Jung} and Kim, {Yang Soo} and Yun, {Hwan Jung} and Lee, {Soon Il} and Kim, {Min Kyoung} and Park, {Eun Kyung} and Kim, {Won Seog} and Cheolwon Suh",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12459",
language = "English",
volume = "7",
pages = "72033--72043",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

TY - JOUR

T1 - Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma

T2 - Results of a multicenter prospective cohort study

AU - Kim, Seok Jin

AU - Hong, Jun Sik

AU - Chang, Myung Hee

AU - Kim, Jeong A.

AU - Kwak, Jae Yong

AU - Kim, Jin Seok

AU - Yoon, Dok Hyun

AU - Lee, Won Sik

AU - Do, Young Rok

AU - Kang, Hye Jin

AU - Eom, Hyeon Seok

AU - Park, Yong

AU - Won, Jong Ho

AU - Mun, Yeung Chul

AU - Kim, Hyo Jung

AU - Kwon, Jung Hye

AU - Kong, Jee Hyun

AU - Oh, Sung Yong

AU - Lee, Sunah

AU - Bae, Sung Hwa

AU - Yang, Deok Hwan

AU - Jun, Hyun Jung

AU - Kim, Yang Soo

AU - Yun, Hwan Jung

AU - Lee, Soon Il

AU - Kim, Min Kyoung

AU - Park, Eun Kyung

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Central nervous system involvement remains a challenging issue in the treatment of patients with diffuse large B-cell lymphoma. We conducted a prospective cohort study with newly diagnosed diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone to identify incidence and risk factors for central nervous system involvement. Among 595 patients, 279 patients received pre-treatment central nervous system evaluation, and 14 patients had central nervous system involvement at diagnosis (2.3% out of entire patients and 5.0% out of the 279 patients). For those patients, median followup duration was 38.2 months and some of them achieved long-term survival. Out of 581 patients who did not have central nervous system involvement at diagnosis, 26 patients underwent secondary central nervous system relapse with a median follow-up of 35 months, and the median time to central nervous system involvement was 10.4 months (range: 3.4-29.2). Serum lactate dehydrogenase > ×3 upper limit of normal range, the Eastern Cooperative Oncology Group performance status ≥ 2, and involvement of sinonasal tract or testis, were independent risk factors for central nervous system relapse in multivariate analysis. Our study suggests that enhanced stratification of serum lactate dehydrogenase according to the National Comprehensive Cancer Network-International Prognostic Index may contribute to better prediction for central nervous system relapse in patients with diffuse large B-cell lymphoma.

AB - Central nervous system involvement remains a challenging issue in the treatment of patients with diffuse large B-cell lymphoma. We conducted a prospective cohort study with newly diagnosed diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone to identify incidence and risk factors for central nervous system involvement. Among 595 patients, 279 patients received pre-treatment central nervous system evaluation, and 14 patients had central nervous system involvement at diagnosis (2.3% out of entire patients and 5.0% out of the 279 patients). For those patients, median followup duration was 38.2 months and some of them achieved long-term survival. Out of 581 patients who did not have central nervous system involvement at diagnosis, 26 patients underwent secondary central nervous system relapse with a median follow-up of 35 months, and the median time to central nervous system involvement was 10.4 months (range: 3.4-29.2). Serum lactate dehydrogenase > ×3 upper limit of normal range, the Eastern Cooperative Oncology Group performance status ≥ 2, and involvement of sinonasal tract or testis, were independent risk factors for central nervous system relapse in multivariate analysis. Our study suggests that enhanced stratification of serum lactate dehydrogenase according to the National Comprehensive Cancer Network-International Prognostic Index may contribute to better prediction for central nervous system relapse in patients with diffuse large B-cell lymphoma.

KW - Central nervous system

KW - Diffuse large B-cell lymphoma

KW - Lactate dehydrogenase

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84995511596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995511596&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12459

DO - 10.18632/oncotarget.12459

M3 - Article

C2 - 27713132

AN - SCOPUS:84995511596

VL - 7

SP - 72033

EP - 72043

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -